Showing 2941-2950 of 9588 results for "".
Skin Cancer Prevention: Can Laser Therapy Help?
https://practicaldermatology.com/conferences/scale-2023/skin-cancer-prevention-can-laser-therapy-help/20205/Non-ablative fractional laser treatments may dramatically the reduce risk of skin cancer recurrence. Joel L. Cohen, MD, and Mathew M. Avram, MD, JD, discuss the science behind this intriguing finding.Unleashing Revenue Growth:Harnessing Patient Data
https://practicaldermatology.com/topics/practice-management/unleashing-revenue-growth-harnessing-patient-data/26968/Unleashing Revenue Growth: Harnessing Patient DataConnective Tissue Disorders Update 2025: Dr. Vleugels
https://reachmd.com/programs/practical-dermatology/connective-tissue-disorders-update-2025-dr-vleugels/32673/Ruth Ann Vleugels, MD, PhD, recaps her presentation, "Connective Tissue Disorders Update 2025" at Maui Derm 2025. Dr. Vleugels discussed a new therapeutic for systemic lupus, a new FDA-approved option for dermatomyositis, JAK inhibitors, and more.A Case Presentation of Prurigo Nodularis
https://practicaldermatology.com/programs/dermatology-hub-neuroimmune-network/derm-hub/37154/Alina Bridges, DO, Director of Dermatopathology & Associate Professor in the Department of Dermatology and Anatomic Pathology at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, presents a case study involving a patient who had been on multiple treatments to present prurituGEP Testing for Cutaneous Squamous Cell Carcinoma
https://practicaldermatology.com/series/updates-in-skin-cancer/gep-testing-for-cutaneous-squamous-cell-carcinoma/35599/Emily Ruiz, MD, MPH, FAAD, director of the High-Risk Cancer Clinic at Dana-Farber Cancer Institute, discusses utilizing gene expression profiling (GEP) to risk stratify tumors in cutaneous squamous cell carcinoma patients.The Impact of Clascoterone Topical Cream, 1%
https://practicaldermatology.com/issues/april-2025/the-impact-of-clascoterone-topical-cream-1/35605/Clascoterone topical cream, 1% (Winlevi, Sun Pharmaceuticals, Inc.) approved by the US Food and Drug Administration (FDA) in 2020 as the first novel drug introduced for the treatment of acne vulgaris since 1982, is indicated in the US for patients 12 years of age and older.The View from Under the Hood
https://practicaldermatology.com/issues/january-february-2025/the-view-from-under-the-hood/32967/As 2025 brings new approvals for treatments for hidradenitis suppurativa, chronic spontaneous urticaria, psoriatic arthritis, and several other diseases that need answers, this is a good time for us to remember that the most important approach to treatment starts with the right diagnosis.Dupilumab's Impact on Height, 40-GEP for HNcSCC Lead Posters at Maui Derm
https://reachmd.com/programs/practical-dermatology/dupilumabs-impact-on-height-40-gep-for-hncscc-lead-posters-at-maui-derm/32916/The impact of dupilumab on children’s height and the 40-gene expression profile (40-GEP) test for patients with cutaneous squamous cell carcinoma of the head and neck (HNcSCC) were the topics of the top two posters in the “Late Breakers 2025” session at Maui Derm 2025 in Maui, Hawaii.Why you need to update your Google My Business profile
https://practicaldermatology.com/topics/practice-management/why-you-need-to-update-your-google-my-business-profile/19911/Google My Business has some very interesting new and upcoming features. Watch this short video from Ekwa Marketing to learn what they are and how you can put them to work for your dermatology practice.Psoriasis and Inflammatory Disease Management Today
https://practicaldermatology.com/topics/psoriasis/psoriasis-and-inflammatory-disease-management-today/19885/COVID-19 can have implications for psoriasis management. Jashin Wu, MD, founder of San Diego Dermatology Symposium, provides guidance on management and introduces the Inaugural Symposium for Inflammatory Skin Disease, coming virtually in April.